Ranvier is building the infrastructure for a $300B+ addressable market at the intersection of diagnostics, digital health, and neurodegenerative care. Our platform targets some of the most misdiagnosed and undertreated conditions in medicine; beginning with depression, Parkinson’s, and Alzheimer’s.

Our commercial model spans direct-to-consumer testing, strategic partnerships with health systems and insurers, and collaborations with pharmaceutical companies and CROs. IP is secured across all core technologies, including patented sensory diagnostics and proprietary blood biomarker panels. Clinical validation is underway in partnership with leading academic and commercial research institutions.

Ranvier is guided by a world-class advisory team spanning neuroscience, artificial intelligence, regulatory science, and healthcare commercialisation. With a low-cost, scalable manufacturing model and multiple revenue streams across consumer, clinical, and research markets, we are positioned to redefine how mood and brain disorders are diagnosed and managed globally.

Join us as we scale evidence-based tools for early detection, longitudinal monitoring, and precision treatment.